1 Disclosure as required by Accounting Standard - AS 17 “Segment Reporting”, issued by the Institute of Chartered Accountants of India.
The entire operations of the Company relate to only one segment viz. “Pharmaceuticals”. As such, there is no separate reportable segment under Accounting Standard-AS 17 on Segment Reporting.
2 Disclosure as required by Accounting Standard - AS 20 “Earning Per Share”, issued by the Institute of Chartered Accountants of India.
The Company has not issued any potential diluted equity share and therefore the Basic and Diluted earning per Share will be the same. The earning per share is calculated by dividing the profit after tax by weighted average number of shares outstanding.
3 In the opinion of the Board of Directors, all the assets other than fixed assets and non current investments have value on realization in the ordinary course of business at least equal to the amount at which they are stated in the Balance Sheet.
4 The Balance Sheet, Statement of Profit & Loss, Cash Flow Statement, Statement of significant accounting policy and other explanatory notes form an integral part of the financial statements of the Company for the year ended on 31st March, 2017
5 Previous year’s figures have been regrouped and re-arranged wherever necessary to make them comparable.
|